High-Intensity Focused Ultrasound Ablation in Treating Patients With Localized Prostate Cancer

OBJECTIVES:

Primary

• To evaluate feasibility, side effect profile, and patient acceptability of high-intensity focused ultrasound ablation in patients with organ-confined, MRI and histologically proven adenocarcinoma of the prostate.

Secondary

• To determine the effectiveness of therapy via biopsy, MRI, PSA level and estimated time to PSA nadir, and by recording the need for secondary or adjuvant treatment following therapy.

OUTLINE: A probe is inserted into the rectum. High-intensity focused ultrasound (HIFU) energy using the Sonablate system is delivered to the prostate tissue over approximately 2 hours. Patients are then evaluated over a 12-month period.

Patients undergo multi-sequence MRI within 10-20 days after HIFU to assess the extent and volume of tumor necrosis and again at 6 months to assess for disease recurrence. Blood is collected for PSA levels at baseline and then at 1, 3, 6, 9, and 12 months. Patients also undergo transrectal ultrasound biopsy at 6 months to evaluate disease response.

Patients complete questionnaires at baseline and at 1, 3, 6, 9, and 12 months to evaluate erectile and sexual function, urinary flow and continence, and quality-of-life.

DISEASE CHARACTERISTICS:

• Histologically confirmed adenocarcinoma of the prostate

• Low-risk disease, as defined by the following criteria:

• Gleason grade total ≤ 7 (patterns 3+4 or 4+3 or less acceptable)
• Localized disease (unilateral or bilateral) (stage T2c, N0, M0 or less)
• Serum PSA ≤ 15 ng/mL
• Prostate volume ≤ 40 cc or maximum anterior-posterior length ≤ 40 mm
• Multi-sequence-MRI and transperineal template 5 mm-spaced biopsies performed within the past 6 months
• All malignant areas must be treatable by focal ablation so that approximately 50% of prostate tissue is destroyed and ≥ 1 neurovascular bundle is preserved
• No intraprostatic calcifications making high-intensity focused ultrasound of focal areas of cancer untreatable
• No metastatic disease

PATIENT CHARACTERISTICS:

• Life expectancy ≥ 5 years
• Must be fit for general or regional anesthesia as assessed by Consultant Anesthetist
• No prior rectal fistula
• No American Society of Anesthesiology grades III-IV
• No latex allergies
• No contraindication to MRI scanning (e.g., severe claustrophobia, permanent cardiac pacemaker, or metallic implant likely to contribute significant artifact to images)
• No moderate to severe inflammatory bowel disease

PRIOR CONCURRENT THERAPY:

• No androgen suppression treatment within the past 6 months
• No transurethral resection of the prostate or laser prostatectomy within the past 5 years
• No prior treatment (i.e., radiotherapy, brachytherapy, surgery, laser therapy, chemotherapy, high-intensity focused ultrasound, cryosurgery, thermal therapy, or microwave therapy) for prostate cancer
• No prior significant rectal surgery preventing insertion of transrectal probe